Search

Your search keyword '"Bilianou, H"' showing total 2 results
Start Over Author "Bilianou, H" Publisher elsevier
2 results on '"Bilianou, H"'

1. Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake.

Author

Vlachopoulos C, Koutagiar I, Skoumas I, Terentes-Printzios D, Zacharis E, Kolovou G, Stamatelopoulos K, Rallidis L, Katsiki N, Bilianou H, Liberopoulos E, Miliou A, Kafouris P, Georgakopoulos A, Gardikioti V, Tousoulis D, and Anagnostopoulos CD

Subjects
Aged, Aorta diagnostic imaging, Aorta metabolism, Aortic Diseases blood, Aortic Diseases diagnostic imaging, Biomarkers blood, Carotid Arteries diagnostic imaging, Carotid Arteries metabolism, Carotid Artery Diseases blood, Carotid Artery Diseases diagnostic imaging, Cholesterol, LDL blood, Drug Administration Schedule, Dyslipidemias blood, Dyslipidemias diagnosis, Female, Fluorodeoxyglucose F18 administration & dosage, Greece, Humans, Inflammation Mediators blood, Male, Middle Aged, Positron Emission Tomography Computed Tomography, Predictive Value of Tests, Prospective Studies, Radiopharmaceuticals administration & dosage, Time Factors, Treatment Outcome, Antibodies, Monoclonal, Humanized administration & dosage, Anticholesteremic Agents administration & dosage, Aorta drug effects, Aortic Diseases drug therapy, Carotid Arteries drug effects, Carotid Artery Diseases drug therapy, Dyslipidemias diagnostic imaging, PCSK9 Inhibitors
Published
2019
Full Text
View/download PDF

2. Hellenic Postprandial Lipemia Study (HPLS): Rationale and design of a prospective, open-label trial to determinate the prevalence of abnormal postprandial lipemia as well as its interaction with statins in patients at high- and very high-risk for cardiovascular disease.

Author

Kolovou G, Giannakopoulou V, Kalogeropoulos P, Anagnostopoulou K, Goumas G, Kazianis G, Limberi S, Perrea D, Mihas C, Kolovou V, and Bilianou H

Subjects
Female, Genetic Testing, Greece epidemiology, Humans, Hypertriglyceridemia epidemiology, Hypertriglyceridemia genetics, Male, Multicenter Studies as Topic, Postprandial Period drug effects, Postprandial Period physiology, Prevalence, Prospective Studies, Randomized Controlled Trials as Topic, Risk Factors, Triglycerides blood, Cardiovascular Diseases prevention & control, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypertriglyceridemia prevention & control
Abstract

Fasting and postprandial hypertriglyceridemia have been related to cardiovascular (CV) disease. We describe the design and methods of the Hellenic Postprandial Lipemia Study (HPLS, NCT02163044), a prospective, open-label, randomized, multicentre trial. The study will recruit 900 participants from 8 centers, and aims to determinate the prevalence of abnormal postprandial lipemia in patients at high- and very high-risk for CV disease, the efficacy of statin treatment and other medications on postprandial lipemia, and the interaction between postprandial lipemia and CV risk during a treatment period of 3 years. Participants will be screened in an outpatient lipid clinic setting. METHODS: High- and very high-risk individuals with fasting triglycerides (TGs) <220 mg/dL (2.5 mmol/L) will be included. At baseline visit demographic and clinical characteristics will be recorded. At the first follow-up visit (within 2-4 weeks from baseline), plasma TG concentrations will be measured, following an overnight 12 h fasting period, before and 4 h after ingestion of a commercially available oral fat tolerance test (OFTT) meal. Then a statin will be prescribed. At the second follow-up visit (within 3-5 month from baseline), plasma TG concentrations will be measured again following an overnight 12 h fasting period, before and 4 h after ingestion of OFTT and then patients will be followed annually for 3 years. CONCLUSION: HPLS is the largest trial assessing the effects of statin therapy on postprandial lipemia. Its results will provide useful insight on the prevalence of postprandial lipemia, the efficacy of statins regarding postprandial lipemia and the clinical significance of this effect. Clinical trial registration information The HPLS trial is registered with clinicaltrials.gov (NCT Identifier: NCT02163044)., (Copyright © 2019 Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results